We rank companies based on fund manager, research analyst and news sentiment
ABVX

Abivax
ABVX

$15.31
1.32%
 

About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Employees: 26

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$15
2%
downside
Avg. target
$17
11%
upside
High target
$20
31%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
Morgan Stanley
Vikram Purohit
5%upside
$16
Equal-Weight
Maintained
11 Apr 2024
Leerink Partners
Thomas Smith
31%upside
$20
Outperform
Initiated
14 Nov 2023
Morgan Stanley
Vikram Purohit
2%downside
$15
Equal-Weight
Initiated
14 Nov 2023

Financial journalist opinion